News >

Clovis Ends Development of Rociletinib in Lung Cancer

Jason M. Broderick @jasoncology
Published: Friday, May 06, 2016

Patrick J. Mahaffy

Patrick J. Mahaffy

Clovis has stopped clinical development of rociletinib, its once promising EGFR inhibitor for the treatment of patients with EGFR T790M–mutated non–small cell lung cancer (NSCLC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication